Selinexor
Acute Myeloid Leukemia (AML)
Key Facts
About Karyopharm Therapeutics
Karyopharm Therapeutics is an innovation-driven, commercial-stage company focused on discovering and developing novel oral cancer therapies targeting nuclear export. Its foundational achievement is the FDA approval of selinexor (XPOVIO®) for relapsed/refractory multiple myeloma and diffuse large B-cell lymphoma (DLBCL). The company's strategy leverages its proprietary oral SINE technology platform to expand selinexor into earlier treatment lines and new indications, while developing next-generation compounds like eltanexor and verdinexor to improve tolerability and efficacy. Karyopharm aims to establish XPO1 inhibition as a cornerstone of cancer treatment across a spectrum of malignancies.
View full company profileAbout Karyopharm Therapeutics
Karyopharm Therapeutics is an innovation-driven, commercial-stage company focused on discovering and developing novel oral cancer therapies targeting nuclear export. Its foundational achievement is the FDA approval of selinexor (XPOVIO®) for relapsed/refractory multiple myeloma and diffuse large B-cell lymphoma (DLBCL). The company's strategy leverages its proprietary oral SINE technology platform to expand selinexor into earlier treatment lines and new indications, while developing next-generation compounds like eltanexor and verdinexor to improve tolerability and efficacy. Karyopharm aims to establish XPO1 inhibition as a cornerstone of cancer treatment across a spectrum of malignancies.
View full company profileAbout Karyopharm Therapeutics
Karyopharm Therapeutics is an innovation-driven, commercial-stage company focused on discovering and developing novel oral cancer therapies targeting nuclear export. Its foundational achievement is the FDA approval of selinexor (XPOVIO®) for relapsed/refractory multiple myeloma and diffuse large B-cell lymphoma (DLBCL). The company's strategy leverages its proprietary oral SINE technology platform to expand selinexor into earlier treatment lines and new indications, while developing next-generation compounds like eltanexor and verdinexor to improve tolerability and efficacy. Karyopharm aims to establish XPO1 inhibition as a cornerstone of cancer treatment across a spectrum of malignancies.
View full company profileTherapeutic Areas
Other Acute Myeloid Leukemia (AML) Drugs
| Drug | Company | Phase |
|---|---|---|
| Mipletamig (APVO436) | Aptevo Therapeutics | Phase 1/2 |
| lomonitinib | Lomond Therapeutics | IND-Enabling |
| lonitoclax | Lomond Therapeutics | Phase 1 |
| Menin Inhibitor | Lomond Therapeutics | Discovery |
| AB8939 | AB Science | Phase 1 |
| Small-Molecule Therapeutic | AIkido Labs | Pre-clinical |
| ADI-PEG 20 (pegargiminase) | Polaris Pharma | Phase 1 |
| NC525 | NextCure | Preclinical |
| ACD-101 | Advanced Cellular Dynamics | Phase 1 |
| ABD-3001 | Advanced Biodesign | Phase 1 |
| HC-7366 | HiberCell | Phase 1b |
| Prexigebersen (BP1001) | Bio-Path Holdings | Phase 2 |